New HIV vaccine approach combines nanoparticles and mRNA in first human test

NCT ID NCT05903339

Ongoing ⭐️ VACCINE ⭐️ Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tests a new HIV vaccine strategy in 36 healthy adults without HIV. The vaccine uses ferritin nanoparticles to display HIV envelope proteins, followed by an mRNA boost. The goal is to safely trigger broadly neutralizing antibodies that could protect against many HIV strains. The study focuses on safety and immune response, not prevention.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ferritin nanoparticles with HIV envelope trimers and mRNA lipid nanoparticles
What this could lead to: If successful, this could point toward a vaccine that teaches the immune system to make broadly neutralizing antibodies against HIV, a major step toward preventing infection.
What could go wrong: This is a very early Phase 1 trial with only 36 participants, so it primarily tests safety and immune response, not effectiveness. Many promising vaccine candidates fail in later stages.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

AIDS HIV infectious disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV

Contacts and locations

Locations

Alabama CRS [Site ID: 31788]

Birmingham, Alabama, 35294-2170, United States
BIDMC VCRS [Site ID: 32077]

Boston, Massachusetts, 02215, United States
Brigham & Women's Hospital [Site ID: 30007]

Boston, Massachusetts, 02115, United States
Emory University School of Medicine, The Ponce de Leon Center CRS [Site ID: 5802]

Atlanta, Georgia, 30303, United States
Seattle Vaccine and Prevention CRS [Site ID: 30331]

Seattle, Washington, 98104, United States
Vanderbilt Vaccine (VV) CRS [Site ID: 30352]

Nashville, Tennessee, 37232-2582, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.